

PURPOSE:

To describe the policies and process for storing and managing blood inventory

PRINCIPLE & CLINICAL SIGNIFICANCE:

Principle

Storage of blood and blood components at University of Washington Medical Center Transfusion Services Laboratory (UWMC TSL) and Seattle Cancer Care Alliance Transfusion Support Service (SCCA TSS) must meet the standards mandated by the Food and Drug Administration (FDA), AABB, and any applicable blood supplier requirements related to products that are eligible for return

Inventory quantities must be sufficient to meet the routine patient needs, allow for unanticipated increases in utilization due to emergencies and minimize component outdating

Clinical Significance

Strict storage requirements are in place to assure the safety, purity, and potency of all blood components are maintained

POLICIES:

Storage of Blood Components

- Only trained UWMC TSL and SCCA Alliance Lab staff are allowed access to blood components prior to components being issued for transfusion. Access is controlled through badge access or 24/7 staff monitoring
- Blood components are stored as specified in **Table 1**: *Blood Component Storage Conditions*. Components not maintained in these storage conditions will be evaluated by the transfusion staff and disposed of as necessary.

Type of Component	Storage Equipment	Storage Temperature			
Red blood cells	Refrigerator	1° to 6°C			
 Thawed plasma 					
 Frozen plasma 	Freezer	≤ -18°C			
Frozen cryoprecipitate					
Platelets	Platelet Incubator with	20° to 24°C with gentle			
	agitator	agitation			
 Granulocytes 	Platelet Incubator	20° to 24°C no agitation			
• Thawed cryoprecipitate					

Table 1: Blood Component Storage Conditions

- Storage equipment temperatures are monitored 24/7 using a wireless electronic monitoring system that alarms if temperatures exceed the acceptable range. Additionally, integral equipment alarms are validated, maintained, and operated as a backup system to the wireless system.
- TSL medical director approval is required prior to placing blood components back into inventory when it is determined that required storage conditions were not maintained. When this occurs, the deviation from SOP must be documented including the reason for the deviation
- Inventory is monitored to ensure units are segregated appropriately in storage in the following manner:
 - Units are segregated by blood type and component type and may also be stored in numerical order (last 6 digits of unit number) to facilitate location of units in inventory
 - Quarantined, autologous and directed units must be physically segregated from other stock
 - Units may additionally be segregated prior to issue, transport, irradiation, or while testing is in progress

Inventory Management

- Inventory levels are maintained between the minimum and par levels in order to provide prompt patient care and reduce wastage (see Appendix: Tables 1 thru 4). These levels are defined at each inventory location/facility and should be considered guidelines that can be adjusted as necessary in response to patient needs
- Inventory levels are monitored by each shift, with orders placed daily with additional orders as needed to ensure the laboratory is able to respond to patient needs in a timely manner
- Inventory quantities are reconciled daily at each site

SPECIMEN REQUIREMENTS:

NA

REAGENTS/SUPPLIES/EQUIPMENT:

Reagents:	Supplies:	Equipment:			
NA	NA	NA			

QUALITY CONTROL:

NA

INSTRUCTIONS:

TABLE of CONTENTS

Daily Inventory Reconciliation (UW TSL and SCCA Staff) Restocking SCCA and 2nd Floor OR Locations (UW TSL staff only)

Daily Inventory Reconciliation (UW TSL and SCCA Staff)

STEP	ACTION
1	Access BBR13: Blood Bank Inventory Summary from SmarTerm and enter the following in the corresponding fields:

Number: PC-0011.01

	Field		Enter							
	Hospital		U							
	Area		 No area (for UW TSL Only) SA1 (for SCCA only) BB2 (for UW 2nd OR only) <enter> (for all area)</enter> 							
	Component type		RBCG							
2	Repeat step one ente	ring the component typ	e for platelets: PLG							
3	Repeat step one ente	ring the following plasr	na component types: PLSG, CRYG							
4	Count the number of r count on the Blood Ba	ed blood cell and plate	elet units by blood type and record the / Report							
5	Count the number of p	plasma and cryoprecip	tate units by blood type and record the							
-	count on the Blood Ba	ink Inventory Summary	/ Report	-						
	Compare the physical count to the count on the SQ report, investigate and resolve any discronancies:									
	Discrepancy		Then							
	None or resolved	Go to next step	1							
	Unresolved Print a BBR2: Product File List for the component type with the									
6	200	 Press the <en Type/Group</en Enter the code discrepancy RBCG PLG fc PLSG CRYG Enter the statu INV to allocat Enter the ABC Press <enter></enter> Compare all u in inventory. 	ter> key for all options until Component e for the component group with the for red blood cells or platelets for plasma for cryoprecipitate us get all available, unprocessed and ed units 0/Rh: (ex: O-POS) for all other options nits listed on report to the units physically							
		Resolved	Go to next step							
		Unresolved	 Document discrepancy on a QIM and notify the TSL Lead Go to next step 							
7	Initial and date Blood	Bank Inventory Summ	ary reports							
0	lf	Then								
Ö	SCCA	Send reports and di	screpancy paperwork to UW TSL]						

UW TSL File reports and discrepancy paperwork in the appropr location	iate
--	------

Restocking SCCA and 2nd Floor OR Locations (UW TSL staff only)

STEP	ACTION
1	Send blood components to the SCCA and 2 nd Floor OR to meet par levels and patient needs (see <u>Appendix: Tables 1-3</u>)
2	Irradiate additional red blood cell and platelet units to maintain acceptable inventory levels (see <i>Appendix: Tables 1-3</i>)

CALCULATIONS/INTERPRETATIONS/RESULTS REPORTING/NORMAL VALUES/CRITICAL VALUES

NA

CALIBRATION:

NA

PROCEDURE NOTES AND LIMITATIONS:

- Due to inventory shortages, it may not be possible to completely fill orders and adjustments may be necessary to optimize product distribution at remote storage locations
- Consult with MLS staff as necessary when short-dated and/or alternate products are offered as a substitution prior to accepting
- Special precautions may be required to prevent burns when handling dry ice. Insulated gloves must be worn when there is a risk of contact with skin. Dry ice should always be handled in a well-ventilated area and must be packaged in a manner that would allow the gas to escape as the dry ice dissipates. See the Clinical Laboratory Safety Policy for additional information and precautions regarding handling dry ice.

REFERENCES:

- Technical Manual. Bethesda, MD: AABB, current edition
- Standards for Blood Banks and Transfusion Services. Bethesda, MD; AABB, current edition

RELATED DOCUMENTS:

NA

APPENDICES:

Table 1: UWMC TSL Inventory Par Levels

	Leukoreduced RBC Components (~ 10% irradiated)														
OF	os	*O N	IEG	A POS A NEG B POS				POS	BN	IEG	AB POS		AB NEG		
Min	Par	Min	Par	Min	Par	Min	Par	Min	Par	Min	Par	Min	Par	Min	Par
70	100	10	15	50	85	8	15	10	15	2	6	\ge	\times	\times	\times
*1 0	NEG	RBC	, Leu	Ikore	duced	unit	for no	eona	tes						
	Plasma														
	(Includes frozen & thawed, Jumbo plasma counts as two units)														
	C)			Α				E	3			Α	В	
Μ	lin	Pa	ar	Ν	1in	P	Par	Ν	1in	P	ar	М	in	Pa	ar
5	0	10	0	5	50	1	00	2	25	5	0	1	0	2	0
		P	oole	d Cry	oprec	ipitat	te			υ,	Single	e Cryc	prec	ipitate	e
				Any	Туре							AB	only		
					30							2	2		
Mini	mum i	invent	tory =	: 10 po	ools & ´	l sing	le AB	units f	or neo	nates					
					Leuko	redu	ced P	latele	et Inve	entor	y				
						(~	50% iı	radia	ted)						
0	POS	0	NEG		A POS		A NE	G B PC		DS	B	NEG AB		POS or	NEG
	8		3		8		4	4 2 2				2			
Mini	mu <mark>m</mark> i	invent	ory =	: 10 a	dult uni	s									

Table 2: UWMC 2 nd Flo	oor Inventory Par Levels

	Leukoreduced RBC Components (~ 10% irradiated)														
OP	OS	O N	EG	A P	OS	AN	À NEG		B POS		IEG	AB	POS	AB I	NEG
Min	Par	Min	Par	Min	Par	Min	Par	Min	Par	Min	Par	Min	Par	Min	Par
10	20	5	10	10	25	2	5	0	5	0	2	\ge	\times	\times	\ge
	Plasma (Thawed)														
	C)			A	L .			E	3		AB			
М	in	Pa	ar	Mi	'n	Par		M	in	P	ar	М	in	Pa	ar
)	2		0		2		()	()	2	2	2	4

	Leukoreduced RBC Components (100% Irradiated)														
ΟΡ	os	O N	O NEG A POS		OS	A NEG		B POS		B NEG		AB POS		AB NEG	
Min	Par	Min	Par	Min	Par	Min	Par	Min	Par	Min	Par	Min	Par	Min	Par
8	18	4	8	8	15	4	8	2	6	2	4	\ge	\times	\geq	\times
				l	Leuko	oredu (10	ced P 00% Ir	latele radiate	e t Inve ed)	entory	/				
0	POS	C) NEG	i	A PO	S	AN	IEG	В	POS		B NEG		AB/ B	NEG
	2 1 2		2		2		1			1		1			
Miniı	mum i	nvent	ory =	5 adul	t units							•			

Table 3: SCCA Inventory Par Levels (100% Irradiated)

Table 4: Total Par Inventory

	Leukoreduced RBC Components														
ΟΡ	OS	0 N	IEG	A P	OS	A۱	NEG	BF	os	B NEG		AB POS		AB NEG	
Min	Par	Min	Par	Min	Par	Min	Par	Min	Par	Min	Par	Min	Par	Min	Par
88	138	19	33	68	125	14	28	12	26	4	12	\geq	\geq	\ge	\succ
	Plasma														
(FFP + FP24 + thawed)															
	C)			ŀ	4			E	3			Α	В	
М	in	Pa	ar	Μ	in	F	ar	N	lin	P	ar	M	lin	Pa	ar
5	0	10)2	5	0	1	02	2	25	50		1	2	2	4
	P	ooleo	d Cryo	prec	ipitat	е			9	Single	e Cryo	opreci	ipitate	9	
			Any [·]	Гуре				AB							
			3	0	X			2							
Minir	num i	nvent	ory =	10 poc	ols & 1	single	e AB ur	nits for	neona	ates					
					_eukc	oredu	iced P	latele	et Inve	entory	/				
						(~	50% i	rradiat	ed)						
OF	POS	0	NEG		A POS	;	A NE	G	B PO	DS	BN	NEG	AB	POS or	NEG
1	0		4		10		6		5			4		3	
		M	inimu	m inv	entory	/ = 20	adult	units							

Number: PC-0011.01

UWMC SOP Appro	oval:	
UWMC CLIA Medical Director	Mark H. Wener, MD	_ Date
Transfusion Service Manager	Deanne Stephens	_ Date
Compliance Analyst	Christine Clark	Date
Service Medical Director	John R. Hess. MD	_Date
UWMC Biennial Re	eview:	
		Date
		_ Date
SCCA SOP Approv	val:	
SCCA CLIA Medic	al Brent L. Wood, MD	Date
Director, Transfus Services		Date
	Terry Gernsheimer, MD	
Alliance Lab Mana	ger	Date
SCCA Biennial Re	view:	
Ŧ		Date
		Date